Subject: MRR
Female Infertility Drugs Market to Grow by USD 538.69 mn | AbbVie Inc. and Aurobindo Pharma Ltd. Among Key Vendors | Technavio
NEW YORK, Dec. 13, 2021 /PRNewswire/ -- The female infertility drugs market is expected to be dominated by North America, with the region accounting for 35% of the market's growth during the forecast period. The US and Canada are the key countries for the female infertility drugs market in North America. However, the growth rate of the market in the region will be slower than the growth of the market in Asia and Europe. The rising prevalence of female infertility, adverse outcomes, and the high cost of non-therapeutic treatments will drive the growth of the female infertility drugs market in North America during the forecast period.
Download Our Free Sample Report and gain access to information related to the latest drivers impacting the growth of the female infertility drugs market
The female infertility drugs market is set to grow by USD 538.69 mn from 2020 to 2025. The growth momentum of the market will progress at a CAGR of 4.71% during the forecast period. The year-over-year growth rate of the market in 2021 is 3.97%. This report provides a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters.
The female infertility drugs market report offers a comprehensive analysis of the various strategies adopted by vendors and the trends, drivers, and challenges affecting the market size. Technavio analyzes the market by route of administration (parenteral, oral, and vaginal) and geography (North America, Europe, Asia, and ROW).
The female infertility drugs market covers the following areas:
Female Infertility Drugs Market Sizing
Female Infertility Drugs Market Forecast
Female Infertility Drugs Market Analysis
Market Segmentation Analysis
The parenteral segment is expected to have significant market share growth of the female infertility drugs market during the forecast period. Drugs approved in this segment mainly include peptide hormonal preparations that mimic the physiological effects of gonadotropins. These hormonal analogs are generally used as fertility medication for ovarian hyperstimulation and reversal of ovulation. The parenteral route is more convenient for these peptide drugs, as they are prone to degradation when administered through the oral route. Hence, these drugs display high bioavailability when administered through the parenteral route.
Companies Mentioned
- AbbVie Inc. - The company offers female infertility drugs, which are elagolix, estradiol, and norethindrone acetate capsules which are packaged for oral use, under the brand name of ORIAHNN and ORILISSA.
- Aurobindo Pharma Ltd. - The company offers female infertility drugs that are available in 2.5 mg capsules which are round in shape, under the brand name of Methotrexate.
- Dr. Reddys Laboratories Ltd. - The company offers female infertility drugs that are available in the form of 10 mg capsules where each tablet contains 297.0 mg lactose, under the brand name Everolimus.
- Ferring B.V. - The company offers female infertility drugs that contain 100 mg progesterone per tablet and is indicated for luteal support as part of an assisted reproductive technology treatment program, under the brand names of LUTINUS and ENDOMETRIN.
- Lupin Ltd. - The company offers female infertility drugs which have an active ingredient Letrozole and are available in forms of tablets under the brand name LUTRAZOLE.
Subscribe to our "Lite Plan" billed annually at USD 3000 to join a community, who are eligible to view 3 reports monthly and download 3 reports annually.
Related Reports:
- Cancer Immunotherapy Market: The cancer immunotherapy market has been segmented by type (monoclonal antibodies, cancer vaccines, and check point inhibitors and immunomodulators) and geography (North America, Europe, Asia, and ROW). Download Free Sample Report
- Urinary Tract Infection Treatment Market: The urinary tract infection treatment market has been segmented by disease type (uncomplicated UTI and complicated UTI) and geography (North America, Europe, Asia, and ROW).Download Free Sample Report
Female Infertility Drugs Market Scope | |
Report Coverage | Details |
Page number | 120 |
Base year | 2020 |
Forecast period | 2021-2025 |
Growth momentum & CAGR | Accelerate at a CAGR of 4.71% |
Market growth 2021-2025 | USD 538.69 million |
Market structure | Fragmented |
YoY growth (%) | 3.97 |
Regional analysis | North America, Europe, Asia, and ROW |
Performing market contribution | North America at 35% |
Key consumer countries | US, Canada, Germany, China, and UK |
Competitive landscape | Leading companies, competitive strategies, consumer engagement scope |
Companies profiled | AbbVie Inc., Aurobindo Pharma Ltd., Dr. Reddys Laboratories Ltd., Ferring B.V., Lupin Ltd., Merck KGaA, Mylan NV, Novartis AG, Sanofi SA, and Takeda Pharmaceutical Co. Ltd. |
Market Dynamics | Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and future consumer dynamics, market condition analysis for the forecast period |
Customization purview | If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/
SOURCE Technavio
These press releases may also interest you
|
News published on and distributed by:
